ATIC Deficiency

ATIC deficiency is a very rare, inherited metabolic disease. It happens when both copies of the ATIC gene do not work properly. The ATIC gene makes a single enzyme that does two final steps in the body’s “make-from-scratch” (de novo) pathway for purines, which are building blocks for DNA, RNA, and energy molecules. When ATIC is faulty, an intermediate called AICAR (also measured as AICA-riboside) builds up in blood and urine, and normal purine production is reduced. The brain, eyes, growth, and development are affected. Many patients have severe developmental delay, seizures that start early, poor growth before and after birth, severe vision problems, and scoliosis. The condition is autosomal recessive (both parents usually carry one faulty copy). Because so few patients are known, our knowledge comes from case reports and small series. PubMedOrphaPMCGenetic Diseases Info Center

ATIC deficiency is a very rare genetic condition that blocks the last steps of the body’s de-novo purine making pathway—the internal “factory” that builds purines, which cells need for DNA/RNA, energy, and signaling. The ATIC gene makes a two-in-one enzyme (AICAR transformylase/IMP cyclohydrolase). When it does not work, a substance called AICAR/ZMP builds up. This buildup likely alters energy-sensing pathways (for example through AMPK), and developing brain, eyes, bones, and growth can be severely affected. Reported features include early developmental delay, low muscle tone, seizures, severe vision loss from chorioretinal damage, scoliosis, and poor growth. Diagnosis rests on the clinical picture, finding the AICAR-related metabolite pattern, and confirming biallelic ATIC variants by genetic testing. Today, there is no established disease-specific treatment; care focuses on seizure control, feeding and nutrition, mobility, vision and posture, communication support, and family counseling. PMCGenetic Diseases Info CenterWiley Online LibraryOrpha

---

Other names

ATIC deficiency is also known as AICA-ribosiduria, 5-amino-4-imidazole-carboxamide ribosiduria, and AICAR transformylase/IMP cyclohydrolase (PURH) deficiency. These names come from the chemical (AICAR) that accumulates in body fluids and from the two catalytic activities of the ATIC enzyme (AICAR transformylase and IMP cyclohydrolase). The disease reflects failure of the last two steps of de novo purine synthesis. Clinically it is characterized by profound neurodevelopmental impairment, early-onset epilepsy, severe visual impairment, ante- and post-natal growth restriction, and skeletal problems such as scoliosis; additional features can include coarse facial features and, in some reports, cardiac, hepatic, renal, or genital findings. PMCWiley Online LibraryGlobal Genes

---

Types

Although there is no universally formal “type” system, clinicians often describe severity groups based on residual enzyme activity, age at seizure onset, vision involvement, and overall development:

1. Severe/Classic AICA-ribosiduria. Early-onset seizures, profound developmental impairment, severe visual loss, and marked growth failure; urine AICA-riboside very high. PMCGenetic Diseases Info Center

2. Intermediate form. Significant developmental delay and epilepsy, often with visual impairment and scoliosis, but with some acquired skills; biochemical elevation is consistent but may be lower than in severe cases. Wiley Online Library

3. Attenuated form. Milder global delay and less frequent or later-onset seizures; vision may be variably affected; very rare and described only recently as the spectrum has expanded. Wiley Online Library

This spectrum likely reflects which domain is affected (transformylase vs cyclohydrolase) and how much activity remains. PMC

---

Causes

ATIC deficiency is a single-gene, autosomal recessive condition. The “causes” below group the different molecular mechanisms by which biallelic ATIC variants can reduce or abolish enzyme function and disturb purinosome biology. (In practice, most patients have two damaging ATIC variants.)

1. Biallelic missense variants in the AICAR transformylase domain that reduce catalytic efficiency. PMC

2. Biallelic missense variants in the IMP cyclohydrolase domain that impair ring-closure activity. PMC

3. Compound heterozygosity for a missense and a truncating (nonsense/frameshift) variant. PMC

4. Homozygous truncating variants leading to markedly decreased or absent protein. PMC

5. Splice-site variants that disrupt correct mRNA processing and lower enzyme levels. Wiley Online Library

6. Promoter or regulatory variants that reduce ATIC expression. (Rare but mechanistically plausible in Mendelian disorders.) Wiley Online Library

7. Exonic deletions/duplications (copy-number variants) encompassing part or all of ATIC. Wiley Online Library

8. Large chromosomal microdeletions including the 2q35 region where ATIC resides. Orpha

9. Uniparental isodisomy of chromosome 2 leading to homozygosity for a pathogenic ATIC variant. (General Mendelian mechanism; consider when parents are non-carriers by testing.) Wiley Online Library

10. Pathogenic variants that destabilize the ATIC protein, causing rapid degradation and loss of function. PMC

11. Variants that impair substrate binding in either catalytic site. PMC

12. Variants that impair formyl-transfer (transformylase) chemistry, selectively reducing that activity. PMC

13. Variants that impair IMP cyclohydrolase activity while sparing transformylase, leaving partial, imbalanced function. PMC

14. Altered purinosome assembly because of ATIC changes, reducing pathway flux. Oxford Academic

15. Deep intronic variants that create cryptic splice sites (rare; requires RNA studies to detect). Wiley Online Library

16. Founder mutations in small or consanguineous populations causing recurrent homozygous disease. Wiley Online Library

17. Mosaicism in a parent, leading to recurrence despite apparently negative standard carrier testing. Wiley Online Library

18. Trans-acting effects from nearby regulatory elements that specifically down-regulate ATIC transcription. Wiley Online Library

19. Post-translational modification defects of ATIC (e.g., altered stability), secondary to coding variants. PMC

20. Very rare multi-locus disease, where an ATIC variant co-occurs with variants in other purine-pathway genes, worsening the phenotype. (The purine pathway is tightly integrated; combined effects are biologically plausible but extremely rare.) Oxford Academic

Note: Environmental “triggers” do not cause ATIC deficiency; they might only modify symptoms in an individual who already has biallelic pathogenic ATIC variants.

---

Symptoms and clinical features

1. Global developmental delay or severe developmental impairment. Children may sit, stand, speak, and learn much later than peers; some never gain independent walking or speech. This reflects reduced purine availability and metabolite toxicity affecting brain development. Genetic Diseases Info Center

2. Early-onset seizures (epilepsy). Seizures often begin in infancy; control can be difficult. Abnormal purine metabolism disrupts neuronal excitability. Genetic Diseases Info Center

3. Severe visual impairment. Some patients have profound vision loss related to retinal/chorioretinal changes; they may not fix or follow. Global Genes

4. Ante- and post-natal growth restriction. Babies may be small at birth and grow poorly afterward, reflecting global metabolic stress. Genetic Diseases Info Center

5. Severe scoliosis. Progressive spinal curvature is common in reported cases and needs orthopedic monitoring. Genetic Diseases Info Center

6. Hypotonia (low muscle tone). Infants feel “floppy,” with delayed motor milestones. This can coexist with movement abnormalities. Genetic Diseases Info Center

7. Feeding difficulties and failure to thrive. Poor suck, reflux, and low weight gain may occur, requiring feeding therapy or tube support. Genetic Diseases Info Center

8. Movement disorders. Dystonia or abnormal postures may be seen; mechanisms likely relate to neurotransmission and energy deficits. (Described across purine disorders.) genome.jp

9. Coarse facial features (dysmorphism). A coarse face or upturned nose has been noted in some reports. malacards.org

10. Cardiac anomalies (e.g., aortic coarctation). Rare but reported; screen when clinically indicated. malacards.org

11. Liver enzyme elevations (chronic hepatic cytolysis). Mild, persistent transaminase elevation may occur; monitor hepatology labs. malacards.org

12. Renal issues (e.g., nephrocalcinosis). Kidney calcifications have been described in some patients; renal ultrasound helps assess. malacards.org

13. Genital anomalies (minor). Minor malformations have been mentioned; clinical importance varies. malacards.org

14. Behavioral symptoms. Irritability, sleep disturbance, or autistic features may appear, as seen in several purine pathway defects. Medlink

15. Recurrent hospitalizations/medical fragility. Because of seizures, feeding problems, and orthopedic/vision needs, families often require frequent care and multidisciplinary support. Genetic Diseases Info Center

---

Diagnostic tests

A) Physical examination

1. Growth assessment (weight/length/head circumference). Tracks ante- and post-natal growth impairment, which is common in ATIC deficiency. Serial measures show pattern and response to support. Genetic Diseases Info Center

2. Neurologic exam (tone, reflexes, motor milestones). Detects hypotonia, movement abnormalities, and global delay; guides therapy and seizure management. Genetic Diseases Info Center

3. Spine screening for scoliosis. Forward-bend test and posture inspection identify curvature; severe cases need imaging and orthopedic referral. Genetic Diseases Info Center

4. Ophthalmologic bedside checks (fix/follow, pupillary response). Simple observations help flag vision loss early; prompt referral to ophthalmology is essential. Global Genes

5. Dysmorphology exam and systemic review. Looks for coarse facial features and screens for possible cardiac/renal/hepatic involvement that has been reported in some patients. malacards.org

B) Manual tests and standardized clinical tools

6. Developmental screening/assessments (e.g., Bayley Scales). Structured testing quantifies cognitive, language, and motor delay baseline for therapy planning. (Standard in neurodevelopmental disorders.) Genetic Diseases Info Center

7. Gross and fine motor functional testing (PT/OT measures). Hands-on therapist assessments define tone, strength, posture, and hand skills to tailor interventions. (Generic but critical across rare neurometabolic disorders.) Genetic Diseases Info Center

8. Vision functional assessment (preferential looking/LEA tests). Behavioral tests estimate usable vision when formal acuity is hard; results guide low-vision support. Global Genes

9. Feeding and swallow evaluation. Bedside and clinical swallow checks by speech-language pathologists determine safety and need for feeding support. (Common in infants with neurologic disease.) Genetic Diseases Info Center

10. Orthopedic functional evaluation. Range-of-motion and sitting/standing balance tests help plan bracing and physical therapy for scoliosis and hypotonia. Genetic Diseases Info Center

C) Laboratory and pathological tests

11. Urine AICA-riboside (AICAr) quantification by LC-MS/MS. Hallmark biochemical test; detects elevated AICAr excretion. Wiley Online Library

12. Plasma (or dried blood spot) AICAR/ZMP measurement. Confirms systemic accumulation and supports diagnosis alongside urine findings. Wiley Online Library

13. Targeted ATIC gene sequencing. Identifies biallelic pathogenic variants; first-line genetic confirmation. Wiley Online Library

14. Exome/genome sequencing. Useful when targeted testing is unrevealing or to detect atypical variants/CNVs. Wiley Online Library

15. Copy-number analysis (e.g., exome-based CNV, CMA). Detects exonic or larger deletions/duplications involving ATIC. Wiley Online Library

16. Enzyme activity in patient fibroblasts. Research/tertiary test showing low AICAR transformylase and/or IMP cyclohydrolase activity; helped prove causality in seminal cases. PMC

17. RNA studies for splicing defects. cDNA analysis can reveal cryptic splice changes when genomic results are uncertain. Wiley Online Library

18. Broader purine/pyrimidine metabolite profiling. Helps rule in/out other purine defects (e.g., ADSL deficiency) and characterize pathway imbalance. PMC

D) Electrodiagnostic tests

19. EEG (electroencephalography). Evaluates seizure type and burden; informs anti-seizure treatment adjustments. Early-onset epilepsy is frequent. Genetic Diseases Info Center

20. Visual electrophysiology (ERG and VEP). ERG assesses retinal function; VEP assesses visual pathways; both clarify the basis of severe visual impairment. Global Genes

21. Brainstem auditory evoked potentials (BAEP). Useful in global developmental disorders to screen pathway integrity when behavioral testing is limited. (Contextual neurodiagnostic use.) Medlink

22. Peripheral nerve conduction studies (selected cases). Consider if hypotonia suggests neuropathy rather than central hypotonia. (Applied case-by-case in neurometabolic disease.) Medlink

E) Imaging tests

23. Brain MRI. May show nonspecific findings such as cerebral atrophy or delayed myelination in neurometabolic disease; used to exclude other causes and to document baseline. (Specific ATIC patterns are not yet well defined.) Genetic Diseases Info Center

24. Spine radiography or low-dose EOS imaging. Quantifies scoliosis curve magnitude to plan bracing or surgery. Genetic Diseases Info Center

25. Ocular imaging (fundus photography, OCT) in cooperative patients. Documents retinal/chorioretinal changes that correlate with severe vision loss. Global Genes

26. Echocardiography (if clinically indicated). Screens for congenital heart defects such as aortic coarctation reported in some cases. malacards.org

27. Renal ultrasound (if indicated). Looks for nephrocalcinosis that has been described in some reports. malacards.org

Non-pharmacological treatments

Aim: keep explanations straightforward. For each item: description, purpose, mechanism, benefits. (Because your request is very large, I’m giving concise, high-value summaries. Tell me which ones you want expanded further.)

Physiotherapy & Rehabilitation

1. Postural management program
   Description: Daily positioning plans (lying, sitting, supported standing) plus custom seating and head/trunk supports.
   Purpose: Prevent spinal curvature, contractures, and skin injury; improve comfort and breathing.
   Mechanism: Maintains neutral alignment and weight distribution; reduces abnormal muscle pull on the spine/hips.
   Benefits: Less pain, easier care, slower scoliosis/hip subluxation progression; better respiratory mechanics.

2. Range-of-motion (ROM) & stretching
   Description: Gentle, scheduled stretches to major joints; splints as needed.
   Purpose: Reduce stiffness and prevent contractures.
   Mechanism: Low-load, long-duration stretch remodels connective tissue; maintains sarcomere length.
   Benefits: Easier dressing/hygiene; improved comfort and positioning.

3. Strengthening in play/therapy
   Description: Task-specific, low-resistance exercises (reaching, rolling, supported standing).
   Purpose: Build functional strength for transfers and mobility.
   Mechanism: Neuroplasticity and muscle conditioning through repetitive practice.
   Benefits: Better head/trunk control, safer handling, more participation.

4. Balance and trunk control training
   Description: Supported sitting/standing with gradual challenge (wedge seats, therapy balls).
   Purpose: Improve stability for feeding, communication, and mobility.
   Mechanism: Repeated postural reactions enhance core activation and balance strategies.
   Benefits: Fewer falls, more independence.

5. Gait training (with or without devices)
   Description: Body-weight-supported treadmill or over-ground with walkers/AFOs.
   Purpose: Promote stepping patterns and endurance if safe.
   Mechanism: Rhythmic, repetitive stepping cues central pattern generators.
   Benefits: Cardiovascular health; reduced caregiver burden.

6. Orthotics (AFOs, TLSO bracing)
   Description: Ankle-foot orthoses for foot alignment; thoracolumbosacral orthosis for scoliosis support when indicated.
   Purpose: Protect joint alignment, assist standing/walking, slow curve progression.
   Mechanism: External support counters abnormal tone and gravity.
   Benefits: More efficient mobility; potentially slower deformity.

7. Respiratory physiotherapy
   Description: Airway clearance (huff cough, PEP devices), positioning, assisted cough training.
   Purpose: Reduce infections and atelectasis; improve ventilation.
   Mechanism: Mobilizes secretions and improves lung expansion.
   Benefits: Fewer hospitalizations; better energy.

8. Feeding/swallow therapy (SLP-led)
   Description: Texture modification, pacing, oral-motor exercises, safe-swallow strategies.
   Purpose: Reduce aspiration/choking; support nutrition.
   Mechanism: Compensatory postures and graded exposure strengthen safe swallow patterns.
   Benefits: Safer feeding; better growth and hydration.

9. Occupational therapy for daily living
   Description: Training for dressing, hygiene, seating, and fine-motor play; adaptive tools.
   Purpose: Maximize independence and reduce caregiver strain.
   Mechanism: Task adaptation and environmental modifications.
   Benefits: Improved quality of life and participation.

10. Vision rehabilitation & low-vision aids
    Description: Lighting, high-contrast materials, tactile cues, magnifiers, and orientation & mobility training.
    Purpose: Work around retinal/visual pathway damage.
    Mechanism: Sensory substitution and environmental adaptation.
    Benefits: Safer mobility; better access to communication and learning. Genetic Diseases Info Center

11. Spasticity/dystonia management (therapy side)
    Description: Serial casting, positioning, and tone-reducing techniques paired with medical care.
    Purpose: Reduce painful spasms and improve function.
    Mechanism: Prolonged stretch and reflex-modulating handling.
    Benefits: Easier care; better tolerance of standing and seating.

12. Hydrotherapy
    Description: Guided movement in warm water.
    Purpose: Enable active exercise with less joint load.
    Mechanism: Buoyancy and warmth reduce tone and pain.
    Benefits: Enjoyable cardio; smoother movement practice.

13. Constraint-induced movement therapy (as appropriate)
    Description: Encouraging use of weaker limb by limiting the stronger side in play blocks.
    Purpose: Improve limb use and brain–body mapping.
    Mechanism: Repetitive, task-specific training drives cortical plasticity.
    Benefits: Better reach, grasp, and bilateral tasks.

14. Seating and mobility technology
    Description: Custom wheelchairs, headrests, tilt-in-space, pressure care cushions.
    Purpose: Comfort, pressure injury prevention, community access.
    Mechanism: Mechanical redistribution of pressure and optimized posture.
    Benefits: Longer upright time; fewer skin problems.

15. Sleep hygiene program
    Description: Routine, light/noise control, timing, safe bedding; review of nighttime positioning and reflux.
    Purpose: Improve sleep quality, which stabilizes seizures and daytime function.
    Mechanism: Circadian entrainment and trigger reduction.
    Benefits: Better behavior, learning, and caregiver resilience.

Mind-Body, Genetics, and Educational therapies

16. Caregiver training & safe-handling education
    Description: Teaching lifting, transfers, positioning, seizure first-aid, and aspiration prevention.
    Purpose: Safety and consistency at home/school.
    Mechanism: Skills → fewer injuries and emergencies.
    Benefits: Empowered family; better outcomes.

17. Augmentative & Alternative Communication (AAC)
    Description: Switches, picture boards, or speech-generating devices.
    Purpose: Give a reliable voice even with motor/speech limits.
    Mechanism: Alternative pathways for language output.
    Benefits: Lower frustration; better learning and social bonds.

18. Individualized Education Plan (IEP)
    Description: Team-built goals for communication, mobility, sensory access, and life skills.
    Purpose: Protected, structured learning.
    Mechanism: Accommodations + measurable targets.
    Benefits: Steady progress and fair access to education.

19. Behavioral supports & sensory regulation
    Description: Gentle routines, predictable schedules, calming sensory diets.
    Purpose: Reduce distress from sensory overload.
    Mechanism: Environmental control reduces triggers.
    Benefits: Smoother days; better participation.

20. Psychological support for family
    Description: Counseling, peer groups, respite planning.
    Purpose: Reduce burnout, grief, and isolation.
    Mechanism: Coping skills and shared experience.
    Benefits: More stable, sustainable care.

21. Nutrition therapy (dietitian-led)
    Description: Calorie-dense plans; texture and reflux management; micronutrient monitoring.
    Purpose: Combat growth failure; support energy and immunity.
    Mechanism: Optimized intake and safer feeding.
    Benefits: Better growth and fewer illnesses. Genetic Diseases Info Center

22. Low-vision orientation & mobility
    Description: White-cane skills, tactile maps, safe routes.
    Purpose: Independent movement despite visual loss.
    Mechanism: Non-visual navigation strategies.
    Benefits: Safety and confidence.

23. Genetic counseling
    Description: Explain inheritance, recurrence risk, carrier testing, and options for future pregnancies.
    Purpose: Informed decisions for families.
    Mechanism: Risk estimation from ATIC genotype.
    Benefits: Planned care and screening for relatives. PanelApp

24. Clinical research/registry enrollment
    Description: Connecting with natural-history studies or trials (e.g., purine supplementation protocols).
    Purpose: Access to new options and expert centers.
    Mechanism: Structured monitoring and protocolized interventions.
    Benefits: Best-available experimental care. ClinicalTrials.gov

25. Palliative care (needs-based, not end-of-life only)
    Description: Symptom control, goals-of-care talks, and coordinated supports from diagnosis onward.
    Purpose: Comfort, dignity, and family alignment.
    Mechanism: Interdisciplinary symptom and stress management.
    Benefits: Better quality of life throughout the journey.

---

Drug treatments

Important: There is no approved disease-modifying drug for ATIC deficiency. Medicines below are commonly used, off-label and individualized, to treat symptoms such as seizures, tone problems, reflux, sleep issues, or pain. Doses/timing must be set by the treating specialist based on age, weight, comorbidities, interactions, and local protocols. Orphanet and GARD emphasize supportive management at expert centers. OrphaGenetic Diseases Info Center

1. Levetiracetam (anti-seizure)
   Class: Broad-spectrum AED. Purpose: Reduce seizure frequency.
   Mechanism: SV2A modulation stabilizes synaptic release.
   Time: Daily, divided dosing; titrated to effect.
   Side effects: Irritability, somnolence, behavioral changes (watch closely).

2. Clobazam (anti-seizure/benzodiazepine)
   Purpose: Adjunct for refractory seizures/spasms.
   Mechanism: GABA-A positive modulation → neuronal inhibition.
   Time: Scheduled; taper if stopping.
   Side effects: Sedation, drooling, constipation; dependence with long-term use.

3. Valproate (broad-spectrum AED)
   Purpose: Certain generalized seizure types.
   Mechanism: GABAergic effects + sodium channel effects.
   Caution: Hepatic toxicity risk, thrombocytopenia, teratogenic—use only when specialist judges benefit > risk.

4. Topiramate (AED)
   Purpose: Focal/generalized seizures; sometimes tone reduction.
   Mechanism: GABA enhancement, glutamate antagonism, carbonic anhydrase inhibition.
   Side effects: Weight loss, cognitive slowing, kidney stones—hydrate well.

5. Lamotrigine (AED)
   Purpose: Adjunct or monotherapy depending on seizure type.
   Mechanism: Voltage-gated sodium channel blockade.
   Key risk: Rash/Stevens–Johnson—slow titration is essential.

6. Baclofen (antispasticity)
   Purpose: Reduce spasticity and painful spasms.
   Mechanism: GABA-B agonist on spinal interneurons.
   Options: Oral; intrathecal pump in severe cases (specialist center).

7. Tizanidine (antispasticity)
   Purpose: Tone reduction when baclofen inadequate.
   Mechanism: α2-adrenergic agonist reduces polysynaptic reflexes.
   Side effects: Sedation, hypotension; monitor LFTs.

8. Botulinum toxin injections
   Purpose: Focal dystonia/spasticity interfering with care.
   Mechanism: Presynaptic ACh blockade at neuromuscular junction.
   Timing: Every 3–4 months; paired with therapy and splinting.

9. Trihexyphenidyl (anticholinergic for dystonia)
   Purpose: Generalized dystonia with painful postures.
   Mechanism: Central muscarinic blockade.
   Side effects: Dry mouth, constipation, behavioral effects.

10. Melatonin (sleep)
    Purpose: Regulate sleep-wake cycle.
    Mechanism: Melatonin receptor agonism for circadian entrainment.
    Benefit: Better sleep can stabilize seizures/behavior.

11. Proton pump inhibitor or H2 blocker (GERD)
    Purpose: Treat reflux that worsens feeding and sleep.
    Mechanism: Lowers gastric acid; decreases aspiration risk.
    Note: Re-assess periodically to avoid long-term overuse.

12. Vitamin D + calcium (bone health)
    Purpose: Prevent osteopenia from immobility/anticonvulsants.
    Mechanism: Supports bone mineralization.
    Monitor: Levels and renal function.

13. Analgesics (acetaminophen; cautious NSAID use)
    Purpose: Pain from contractures or surgery.
    Mechanism: Central COX inhibition (acetaminophen), peripheral COX (NSAIDs).
    Caution: GI/renal risks with NSAIDs; tailor to patient.

14. Laxatives (PEG, stool softeners)
    Purpose: Treat constipation from low mobility and meds.
    Mechanism: Osmotic water retention or softened stool.
    Benefit: Lower reflux and discomfort; better feeding.

15. Antisialagogues (e.g., glycopyrrolate) or drooling patches
    Purpose: Control drooling/aspiration risk.
    Mechanism: Anticholinergic reduction of salivary flow.
    Side effects: Dry mouth, constipation—monitor.

---

Dietary molecular supplements

Evidence for supplements specifically in ATIC deficiency is limited. Use only under clinician/dietitian guidance; avoid interactions with anti-seizure drugs. Orphanet/GARD emphasize supportive care; 2024 research is exploring purine supplementation under protocol, not routine home use. OrphaGenetic Diseases Info CenterPubMed

1. Purine supplementation (investigational)
   Function: Provide dietary purines to down-regulate de-novo synthesis.
   Mechanism: Salvage pathway use may suppress the blocked pathway flux.
   Note: Trial/center-only, dosing protocolized. PubMedClinicalTrials.gov

2. Omega-3 DHA/EPA
   Supports retinal/neuronal membranes; anti-inflammatory signaling; may aid vision comfort and brain health.

3. Lutein + Zeaxanthin
   Macular pigments for retinal oxidative stress buffering; potential visual-function support in low-vision care.

4. Coenzyme Q10
   Mitochondrial redox cofactor; sometimes used in neuro-metabolic support to improve energy handling.

5. L-Carnitine
   Fatty-acid transport into mitochondria; may help energy metabolism if intake/levels are low.

6. Creatine
   Phosphocreatine energy buffering for muscle/brain; careful use in seizure disorders per specialist.

7. Riboflavin (B2)
   Cofactor for multiple flavoprotein enzymes; general mitochondrial support.

8. Thiamine (B1)
   Cofactor for carbohydrate metabolism; supports energy pathways in high-demand tissues.

9. Folate/Folinic acid
   Methylation/one-carbon support; sometimes tried empirically in purine/one-carbon pathway disorders (evidence limited).

10. Multinutrient formula for tube or oral feeding
    Ensures complete macro/micronutrients when texture-modified diets limit variety.

---

Immunity-booster / regenerative / stem-cell” drugs

There are no approved regenerative or stem-cell drugs for ATIC deficiency. Below are research concepts or supportive measures—not standard of care. Families should discuss risks in expert centers.

1. AAV-mediated ATIC gene replacement (concept)
   Vector delivers functional ATIC to target tissues; theoretical benefit but not in clinical use yet.

2. mRNA therapy (concept)
   Transient delivery of ATIC mRNA to restore enzyme; experimental platform only.

3. CRISPR-based gene correction (concept)
   Genome editing of ATIC variants; currently preclinical, with safety/targeting hurdles.

4. Hematopoietic stem cell transplant (HSCT) (not established)
   Could theoretically supply enzyme from donor cells but would not correct neuronal retina fully; high risk, no evidence.

5. Comprehensive vaccination program (supportive)
   Not a “drug for regeneration,” but essential immune protection to prevent decompensation from infections.

6. Immunonutrition bundle (dietitian-led)
   Protein and micronutrients (vitamins A, C, D, zinc) to support immune function if deficient; adjunct only.

---

Surgeries

1. Gastrostomy tube (G-tube)
   Procedure: Small abdominal opening to the stomach for feeding.
   Why: Poor oral intake, aspiration risk, or severe reflux requiring safer nutrition access.

2. Spinal fusion for progressive scoliosis
   Procedure: Rods/screws to straighten and fuse unstable spine segments.
   Why: Pain, seating difficulty, respiratory compromise from severe curves.

3. Soft-tissue release/tendon lengthening
   Procedure: Lengthen tight muscles (hamstrings, adductors, Achilles).
   Why: Painful contractures limiting care, seating, or bracing.

4. Hip reconstruction (if dysplasia/subluxation)
   Procedure: Bony re-alignment and soft-tissue balancing.
   Why: Pain relief, hygiene, seating tolerance.

5. Ophthalmic procedures (case-by-case)
   Procedure: Strabismus surgery or supportive ocular procedures.
   Why: Comfort, alignment, and care—vision restoration is unlikely with chorioretinal atrophy.

---

Prevention & proactive care tips

1. Early genetic diagnosis and family counseling for future pregnancies. PanelApp

2. Regular seizure review; avoid missed doses/triggers (sleep loss, fever).

3. Vaccinations up-to-date (influenza, pneumococcal, etc.).

4. Aspiration prevention: texture-modified feeds, safe swallow positions.

5. Scheduled dental care to reduce pain/aspiration and improve nutrition.

6. Skin and pressure injury prevention with proper cushions and turning.

7. Bone health monitoring (vitamin D, calcium, weight-bearing if possible).

8. Scoliosis/hip surveillance with periodic imaging/orthopedics.

9. Home airway plan (suction/clearance) for respiratory infections.

10. Enroll with an expert center or rare-disease network; consider registries/trials. OrphaClinicalTrials.gov

---

When to see doctors urgently

• New or worsening seizures, prolonged seizures, or clusters.

• Signs of aspiration (coughing with feeds), dehydration, or weight loss.

• Rapidly worsening scoliosis or pain with sitting/lying.

• Breathing difficulty, recurrent chest infections, or poor airway clearance.

• New vision changes, eye pain, or sudden behavioral decline.

• Any unexplained regression in skills, persistent vomiting, or severe constipation.

---

Diet:  things to eat & to avoid

Eat/Emphasize

1. Calorie-dense, texture-appropriate meals (purees/mash as needed).

2. Healthy fats (olive oil, nut/seed butters if safe), to meet energy needs.

3. Protein with each meal (eggs, dairy, legumes, poultry/fish, or alternatives).

4. Fiber from cooked vegetables/fruit purees and oats to ease constipation.

5. Adequate fluids and safe-thickened liquids if advised.

6. Vitamin-D-fortified foods and dairy/alternatives for bone health.

7. Omega-3 sources (fish, flax) for general neural/retinal support.

8. Iron-rich foods (meat/legumes) with vitamin C for absorption.

9. Small, frequent meals to reduce reflux.

10. Dietitian-approved complete formulas if oral intake is poor.

Avoid/Limit

1. Choking hazards (nuts, hard raw veggies) unless safely modified.

2. Highly acidic/spicy foods that worsen reflux.

3. Excess added sugar that displaces nutrients.

4. Dehydration—keep a hydration plan.

5. Alcohol/caffeine in older patients if seizure-triggering.

6. Unsupervised restrictive low-purine diets—not recommended in ATIC deficiency; this disorder affects de-novo synthesis and may require specialist-guided strategies (including investigational purine supplementation in trials). PubMed

7. Unverified supplements that interact with AEDs.

8. Large evening meals if reflux/sleep issues.

9. High-salt ultra-processed foods if edema/GERD.

10. Any “immunity booster” products without clinician review.

---

Frequently asked questions

1. Is there a cure?
   Not yet. Current care is supportive; investigational purine supplementation is being studied in specialized centers. OrphaPubMed

2. How is it confirmed?
   By clinical signs, elevated AICAR-related metabolites, and genetic testing showing ATIC variants. PMCPanelApp

3. Why are brain and eyes affected?
   Developing neurons and retina depend heavily on purine supply; ATIC blockage plus ZMP/AMPK effects likely disrupt development. PMC

4. What about seizures—are they treatable?
   Yes. Seizure control with standard anti-seizure medicines is key, individualized by specialists. Orpha

5. Does a low-purine diet help?
   Not recommended. This condition blocks making purines, not breakdown; specialist teams are testing the opposite idea—carefully adding purines under trial protocols. PubMed

6. Can therapy improve function?
   Physio/OT/SLP and low-vision rehab improve comfort, safety, and participation, even if they cannot reverse the disease.

7. Is vision loss reversible?
   Significant structural retinal damage is generally not reversible; low-vision supports maximize remaining function. Genetic Diseases Info Center

8. Are there many patients?
   Very few worldwide; cases are ultra-rare, with small case series published. Wiley Online Library

9. Can siblings be tested?
   Yes—carrier and targeted testing via genetics teams. PanelApp

10. Will my child need surgery?
    Sometimes—e.g., G-tube, spinal/orthopedic procedures—based on symptoms and team assessment.

11. Does sleep matter for seizures?
    Yes. Consistent sleep hygiene often stabilizes seizures and daytime function.

12. What specialists should be involved?
    Neurology/epileptology, clinical genetics, ophthalmology, physiatry/physiotherapy, dietetics, pulmonology, orthopedics, dental, and palliative care coordination.

13. Are vaccines safe?
    Yes—important to prevent infections that can worsen overall health.

14. How can we join research?
    Ask your genetics/metabolic team about registries and the purine supplementation trial. ClinicalTrials.gov

15. Where can we read more?
    See Orphanet, GARD, and peer-reviewed literature on AICA-ribosiduria/ATIC deficiency. OrphaGenetic Diseases Info Center

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 10, 2025.